USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Yes84% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$42 – $532
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your tradjenta prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Note: This document contains side effect information about linagliptin. Some of the dosage forms listed on this page may not apply to the brand name Tradjenta.
More frequent side effects include: hypoglycemia. See below for a comprehensive list of adverse effects.
Applies to linagliptin: oral tablet
Along with its needed effects, linagliptin (the active ingredient contained in Tradjenta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking linagliptin:
Incidence not known
Some side effects of linagliptin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to linagliptin: oral tablet
Uncommon (0.1% to 1%): Constipation, increased amylase levels
Frequency not reported: Pancreatitis
Postmarketing reports: Acute pancreatitis
During clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin compared with 3.7 cases per 10,000 patient year exposure in those receiving active comparator (sulfonylurea). Following completion of clinical trials, 3 additional cases of pancreatitis were reported among those receiving linagliptin. Postmarketing reports of acute pancreatitis, including fatalities, have been received.
The most common adverse event reported was nasopharyngitis.
Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with this drug. These reactions have occurred within the first 3 months, with some occurring after the first dose.
Frequency not reported: Drug hypersensitivity
Postmarketing reports: Serious hypersensitivity reactions
Common (1% to 10%): Hypoglycemia, hypertriglyceridemia, hyperlipidemia, increased uric acid
The incidence of hypoglycemia in patients treated with this drug as monotherapy, or in combination with metformin or pioglitazone, was similar to the incidence observed in placebo-treated patients. When given in combination with metformin plus a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo with metformin plus a sulfonylurea. As add-on to stable insulin therapy, the incidence of hypoglycemia was similar to placebo (31.4% versus 32.9%).
Postmarketing reports of bullous pemphigoid requiring hospitalization have been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors use. These case typically recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor.
Postmarketing reports: Rash, angioedema, urticaria
Dipeptidyl peptidase-4 inhibitors:
Postmarketing reports: Bullous pemphigoid
Common (1% to 10%): Cough, nasopharyngitis, upper respiratory tract infection
Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database. Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor. In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain. In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation. A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor. Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (the active ingredient contained in Tradjenta) (n=2), alogliptin (n=1), and vildagliptin (n=2).
Common (1% to 10%): Back pain, arthralgia, extremity pain
Common (1% to 10%): Headache
Common (1% to 10%): Urinary tract infection
June 26, 2020
June 25, 2020
June 27, 2020
July 10, 2020
July 9, 2020
July 1, 2020